QualityStocksNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Accomplished Executive Shannon Inman to Drive Launch of Key Clinical Trials

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Shannon Inman as Vice President of Global Clinical Operations. According to the update, Inman will lead in defining clinical developmental strategies, clinical protocol design, study conduct, and managing risk assessment in this new position. These clinical trials include those with Genprex’s lead drug candidate, Oncoprex(TM), for non-small cell lung cancer (“NSCLC”), which recently received Fast Track Designation for its combination with osimertinib, AstraZeneca’s first-line targeted EGFR TKI drug Tagrisso(R). “Genprex continues to strengthen its leadership team with the appointment of an accomplished executive to drive the launch of key clinical trials,” Genprex Chairman and CEO Rodney Varner said in the news release. “Ms. Inman brings a wealth of experience in the pharmaceutical industry, having successfully directed a number of development programs in both large and small biotechnology companies and top tier academic institutions. She will be instrumental in continuing to build the long-term value of our gene therapies. With the addition of our second investigational gene therapy asset addressing the unmet medical need of people suffering from diabetes, I’m excited about building the necessary infrastructure to facilitate our growth.”

To view the full press release, visit http://ibn.fm/oCfHZ

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, Oncoprex(TM), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)). For more information, please visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php